These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 36317596)

  • 1. Living Leukocyte-Based Drug Delivery Systems.
    Chen Y; Qin D; Zou J; Li X; Guo XD; Tang Y; Liu C; Chen W; Kong N; Zhang CY; Tao W
    Adv Mater; 2023 Apr; 35(17):e2207787. PubMed ID: 36317596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage membrane biomimetic drug delivery system: for inflammation targeted therapy.
    Zhang Y; Long Y; Wan J; Liu S; Shi A; Li D; Yu S; Li X; Wen J; Deng J; Ma Y; Li N
    J Drug Target; 2023 Mar; 31(3):229-242. PubMed ID: 35587560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Glycan Derived Biomaterials for Inflammation Targeted Drug Delivery.
    Niu Y; Xue Q; Fu Y
    Macromol Biosci; 2021 Sep; 21(9):e2100162. PubMed ID: 34145960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery strategies of RNA therapeutics to leukocytes.
    Tarab-Ravski D; Stotsky-Oterin L; Peer D
    J Control Release; 2022 Feb; 342():362-371. PubMed ID: 35041904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Advances of Neutrophil-Derived Effective Drug Delivery Systems: A Key Review of Managing Tumors and Inflammation.
    Wang H; Zang J; Zhao Z; Zhang Q; Chen S
    Int J Nanomedicine; 2021; 16():7663-7681. PubMed ID: 34815670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy.
    Wu H; Li W; Hao M; Wang Y; Xue L; Ju C; Zhang C
    Adv Drug Deliv Rev; 2022 Aug; 187():114380. PubMed ID: 35662610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease.
    Mitroulis I; Alexaki VI; Kourtzelis I; Ziogas A; Hajishengallis G; Chavakis T
    Pharmacol Ther; 2015 Mar; 147():123-135. PubMed ID: 25448040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in therapeutic strategies and biomimetic nanomedicines based on neutrophils for inflammation treatment.
    Liu Y; Yu Y; Wang M; Zhang C; Li C
    Nanomedicine (Lond); 2023 Feb; 18(5):485-500. PubMed ID: 37165973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug delivery to macrophages: a review of nano-therapeutics targeted approach for inflammatory disorders and cancer.
    Mukhtar M; Ali H; Ahmed N; Munir R; Talib S; Khan AS; Ambrus R
    Expert Opin Drug Deliv; 2020 Sep; 17(9):1239-1257. PubMed ID: 32543950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer.
    Ponzoni M; Pastorino F; Di Paolo D; Perri P; Brignole C
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29973487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in glycosylation-mediated cancer-targeted drug delivery.
    Cai L; Gu Z; Zhong J; Wen D; Chen G; He L; Wu J; Gu Z
    Drug Discov Today; 2018 May; 23(5):1126-1138. PubMed ID: 29501708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanosize drug delivery system.
    Mukherjee B
    Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of platelets in inflammation.
    Thomas MR; Storey RF
    Thromb Haemost; 2015 Aug; 114(3):449-58. PubMed ID: 26293514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-Based Delivery Systems for Nanotherapeutics.
    Han Y; Zhao R; Xu F
    Small; 2018 Oct; 14(42):e1801674. PubMed ID: 30144279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic strategies based on toll-like receptor signaling.
    Lawton JA; Ghosh P
    Curr Opin Chem Biol; 2003 Aug; 7(4):446-51. PubMed ID: 12941417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Core-shell nanotherapeutics with leukocyte membrane camouflage for biomedical applications.
    Fan M; Jiang M
    J Drug Target; 2020 Nov; 28(9):873-881. PubMed ID: 32298153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases.
    Schraa AJ; Everts M; Kok RJ; Asgeirsdóttir SA; Meijer DK; de Leij LF; Molema G
    Biotechnol Annu Rev; 2002; 8():133-65. PubMed ID: 12436918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered nanoparticles as emerging gene/drug delivery systems targeting the nuclear factor-κB protein and related signaling pathways in cancer.
    Eskandani R; Kazempour M; Farahzadi R; Sanaat Z; Eskandani M; Adibkia K; Vandghanooni S; Mokhtarzadeh A
    Biomed Pharmacother; 2022 Dec; 156():113932. PubMed ID: 36411621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanocarrier-based systems for targeted and site specific therapeutic delivery.
    Majumder J; Taratula O; Minko T
    Adv Drug Deliv Rev; 2019 Apr; 144():57-77. PubMed ID: 31400350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
    Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
    Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.